Emerging evidence highlights the role of thyroid hormones in cancer, though findings are controversial. Research on thyroid-related traits in lung carcinogenesis is limited. Using UK Biobank data, we conducted bidirectional Mendelian randomization (MR) to assess causal links between lung cancer risk and thyroid dysfunction (hypothyroidism/hyperthyroidism) or function traits (free thyroxine [FT4], normal-range TSH). Furthermore, in the smoking-behavior stratified MR analysis, we evaluated the mediating effect of thyroid-related phenotypes on the association between smoking phenotype and lung cancer. We confirmed significant associations between lung cancer risk and hypothyroidism (hazards ratio [HR] = 1.14, 95% confidence interval [CI] = 1.03-1.26, = 0.009) as well as hyperthyroidism (HR = 1.55, 95% CI = 1.29-1.87, = 1.90×10 ) in the UKB. Moreover, the MR analysis indicated a causal effect of thyroid dysfunction on lung cancer risk (OR = 1.09, 95% CI = 1.05-1.13, = 3.12×10 for hypothyroidism; OR = 1.08, 95% CI = 1.04-1.12, = 8.14×10 for hyperthyroidism). We found that FT4 levels were protective against lung cancer risk (OR = 0.93, 95% CI = 0.87-0.99, = 0.030). Additionally, the stratified MR analysis demonstrated the distinct causal effect of thyroid dysfunction on lung cancer risk among smokers. Hyperthyroidism mediated the effect of smoking behavior, especially the age of smoking initiation (17.66% mediated), on lung cancer risk. Thus, thyroid dysfunction phenotypes play causal roles in lung cancer development exclusively among smokers and act as mediators in the causal pathway from smoking to lung cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7555/JBR.38.20240421 | DOI Listing |
Thorac Cancer
March 2025
Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Background: Few malignancies provoke as many controversies about treatment as pleural mesothelioma. There is limited experience with novel radiotherapy techniques worldwide in adjuvant and particularly in neoadjuvant settings within multimodality treatment. The objective of the current study was to investigate the long-term outcome of neoadjuvant and adjuvant pleural intensity-modulated radiotherapy (IMRT) combined with macroscopic complete resection with or without chemotherapy.
View Article and Find Full Text PDFHistol Histopathol
February 2025
Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
Non-small cell lung cancer (NSCLC) is a complex disease with diverse clinical and molecular characteristics. Since the discovery of the oncogenic neurotrophic receptor tyrosine kinase (NTRK) gene fusion in colorectal cancer in 1986, its understanding has gradually progressed. NTRK's relevance is crucial to understanding some tumor development and how specific tyrosine receptor kinase inhibitors (TRKI) work.
View Article and Find Full Text PDFThorac Cancer
March 2025
Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Background: Bone metastasis (BoM) is common in advanced cancer, but its incidence in pleural mesothelioma (PM) remains unclear. This study aimed to determine the incidence of BoM in PM patients and assess its prognosis and risk factors to clarify its clinical significance.
Methods: A retrospective analysis was conducted on 515 histologically confirmed PM patients enrolled between January 2011 and December 2020.
Background: The development of immunotherapy has led to a paradigm shift in the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) function by blocking the receptors and ligands of T cells from binding one another, empowering them to target and attack cancer cells. ICIs along with other immunotherapy treatments, have seen a significant increase in usage in recent years.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!